Status:
ACTIVE_NOT_RECRUITING
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Hereditary Neoplasms
Cancer
Eligibility:
All Genders
Brief Summary
This is a clinical, epidemiologic, genetic, and laboratory study of individuals and families at high risk of cancer and selected tumors to investigate the genetic susceptibility and environmental expo...
Detailed Description
Background: Persons may be prone to develop cancer for a variety of reasons including: inherited predisposition benign, premalignant, or malignant conditions; environmental exposures shared by family...
Eligibility Criteria
- INCLUSION CRITERIA:
On referral, persons of any age will be considered for the inclusion in the study because of either:
A family or personal history of neoplasia of an unusual type, pattern, or number; OR,
known or suspected factor(s) predisposing to neoplasia, either genetic and/or congenital factors (birth defects, metabolic phenotype, chromosomal anomalies or Mendelian traits associated with tumors), environmental exposure (medications, occupation, radiation, diet, infectious agents, etc.), or unusual demographic features (very young age of onset, multiple tumors, etc.).
Personal and family medical history must be verified through questionnaires, interviews, and review of pathology slides and medical records. For familial neoplasms, two or more living affected cases among family members are required. The types of familial tumors that we are currently actively accruing include:
Familial Cancers: bladder, brain, chordoma, lung, nevoid basal cell carcinoma syndrome (NBCC)
Familial Benign Neoplasms: meningiomas, neurofibromatosis 2 (bilateral acoustic neurofibromatosis)
The types of familial tumors under active accrual and study are predominantly investigator-and hypothesis-driven. This approach permits GEB investigators to remain alert to the opportunities afforded by clusters of rare tumors in families and individuals, and to be more responsive to the dynamic research priorities in cancer genetics.
EXCLUSION CRITERIA:
Referred individuals and families for whom reported diagnoses cannot be verified.
Inability to provide informed consent.
Eligible for familial melanoma, lymphoproliferative, breast-ovarian cancer, or testicular cancer protocols.
Key Trial Info
Start Date :
April 2 1985
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
5201 Patients enrolled
Trial Details
Trial ID
NCT00001163
Start Date
April 2 1985
Last Update
March 11 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892